Characterization of formaldehyde-inactivated poliovirus preparations made from live-attenuated strains

Journal of General Virology

Volumn 84, Issue 7, 2003, Pages 1781-1788

  Martín, Javier ^a,b   Crossland, Graham ^a,b   Wood, David J ^a,b   Minor, Philip D ^a,b  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; LIVE VACCINE; POLIOMYELITIS VACCINE; VIRUS RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG SPECIFICITY; ERADICATION THERAPY; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLIOMYELITIS; POLIOMYELITIS VIRUS; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; PROTEIN EXPRESSION; STRAIN DIFFERENCE; TRANSGENIC MOUSE; VIRUS ATTENUATION; VIRUS CHARACTERIZATION; VIRUS INACTIVATION; VIRUS INFECTIVITY; VIRUS STRAIN; WILD TYPE;

ANIMALS; ANTIBODIES, VIRAL; CELL LINE; DISEASE MODELS, ANIMAL; FORMALDEHYDE; HUMANS; IMMUNIZATION; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; RECEPTORS, VIRUS; VIRULENCE;

ANIMALIA; HUMAN POLIOVIRUS 1; MUS MUSCULUS; POLIOVIRUS; RNA VIRUSES;

EID: 0037813169     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.19088-0     Document Type: Article

References (27)

1. Anon. (2001). Acute flaccid paralysis associated with circulating vaccine-derived poliovirus - Philippines, 2001. Morb Mortal Wkly Rep 50, 874-875.
2. Cabasso, V. J., Jervis, G. A., Moyer, A. W., Roca-Garcia, M., Orsi, E. V.&Cox, H. R. (1959). Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. In Live Poliovirus Vaccines. First International Conference on Live Poliovirus Vaccines, pp. 102-134. Washington, DC: Pan American Sanitary Bureau.
3. Centers for Disease Control&Prevention (2001). Circulation of a type 2 vaccine-derived poliovirus - Egypt, 1982-1993. JAMA 285, 1148-1149.
4. Doi, Y., Abe, S., Yamamoto, H.&8 other authors (2001). Progress with inactivated poliovirus vaccines derived from the Sabin strains. Dev Biol 105, 163-169.
5. Dowdle, W. R., Featherstone, D. A., Birmingham, M. E., Hull, H. F.&Aylward, R. B. (1999). Poliomyelitis eradication. Virus Res 62, 185-192.
6. Dowdle, W. R., Gary, H. E., Sanders, R.&van Loon, A. M. (2002). Can post-eradication laboratory containment of wild polioviruses be achieved? Bull World Health Organ 80, 311-316.
7. Ferguson, M., Wood, D. J.&Minor, P. D. (1993). Antigenic structure of poliovirus in inactivated vaccines. J Gen Virol 74, 685-690.
8. Hovi, T. (2001). Inactivated poliovirus vaccine and the final stages of poliovirus eradication. Vaccine 19, 2268-2272.
9. Kersten, G., Hazendonk, T.&Beuvery, C. (1999). Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17, 2059-2066.
10. Kew, O., Morris-Glasgow, V., Landaverde, M.&21 other authors (2002). Outbreak of poliomyelitis in Hispaniola associated with circulating type 1 vaccine-derived poliovirus. Science 14, 14.
11. Koprowski, H. (1958). Vaccination with modified active viruses. In Poliomyelitis. Papers and Discussion Presented at the Fourth International Poliomyelitis Conference, pp. 112-123. Philadelphia: Lippincott.
12. Lu, H. H., Yang, C. F., Murdin, A. D., Klein, M. H., Harber, J. J., Kew, O. M.&Wimmer, E. (1994). Mouse neurovirulence determinants of poliovirus type 1 strain LS - a map to the coding regions of capsid protein VP1 and protenase 2Apro. J Virol 68, 7507-7515.
13. Martin, J.&Minor, P. D. (2002). Characterization of CHAT and Cox type 1 live-attenuated poliovirus vaccine strains. J Virol 76, 5339-5349.
14. McGoldrick, A., Macadam, A. J., Dunn, G., Rowe, A., Burlison, J., Minor, P. D., Meredith, J., Evans, D. J.&Almond, J. W. (1995). Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus. J Virol 69, 7601-7605.
15. Melnick, J. L. (1994). Live attenuated poliovirus vaccines. In Vaccines, pp. 155-204. Edited by S. A. Plotkin&E. A. Mortimer, Jr. Philadelphia: W. B. Saunders.
16. Minor, P. D. (1980). Comparative biochemical studies of type 3 poliovirus. J Virol 34, 73-84.
17. Minor, P. D. (1990). Antigenic structure of picornaviruses. Curr Top Microbial Immunol 161, 121-154.
18. Minor, P. D., John, A., Ferguson, M.&Icenogle, J. P. (1986). Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. J Gen Virol 67, 693-706.
19. Murdin, A. D., Barreto, L.&Plotkin, S. (1996). Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735-746.
20. Murph, J. R., Grose, C., McAndrew, P., Mickiewicz, C., Mento, S., Cano, F., Redick, L., Ritchey, M.&Stout, M. G. (1988). Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey. Pediatr Infect Dis 17, 760-765.
21. Salk, J., Drucker, J. A.&Malvy, D. (1994). Noninfectious poliovirus vaccine. In Vaccines, pp. 205-228. Edited by S. A. Plotkin & E. A. Mortimer, Jr. Philadelphia: W. B. Saunders.
22. Singer, C., Knauert, F., Bushea, G., Klutch, M., Lundquist, R.&Quinnan, G. V., Jr (1989). Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand 17, 137-150.
23. Strebel, P. M., Sutter, R. W., Cochi, S. L., Biellik, R. J., Brink, E. W., Kew, O. M., Pallansch, M. A., Orenstein, W. A.&Hinman, A. R. (1992). Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 14, 568-579.
24. Taffs, R. E., Chernokhvostova, Y. V., Dragunsky, E. M., Nomura, T., Hioki, K., Beuvery, E. C., Fitzgerald, E. A., Levenbook, I. S.&Asher, D. M. (1997). Inactivated poliovirus vaccine protects transgenic poliovirus receptor mice against type 3 poliovirus challenge. J Infect Dis 175, 441-444.
25. Toyoda, H., Kohara, M., Kataoka, Y., Suganuma, T., Omata, T., Imura, N.&Nomoto, A. (1984). Complete nucleotide sequences of all three poliovirus serotype genomes. Implication for genetic relationship, gene function and antigenic determinants. J Mol Biol 174, 561-585.
26. Twomey, T., Newman, J., Burrage, T., Piatti, P., Lubroth, J. &Brown, F. (1995). Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines. Vaccine 13, 1603-1610.
27. World Health Organization (1997). Manual for the Virological Investigation of Poliomyelitis. Geneva: World Health Organization.